Firefly Neuroscience Inc AIFF

$AIFF Firefly’s latest quarter provides the clearest evidence yet that the business is gaining traction. Q3 revenue rose 26% sequentially to $647,000 and 67% year over year, while gross profit more than doubled to $525,000. Gross margin expanded to 81%, operating loss narrowed 22%, and net loss improved 44%. The company says growth was driven primarily by recurring subscription revenue from deployed Evoke equipment. More than 85 U.S. clinical sites are actively using Evoke, and CEO Greg Lipschitz has previously cited scan volume of roughly 1,200–1,500 per month and growing. With Radial and Monarch still early, Firefly may be entering a period where deeper clinic utilization, repeat scans, and new network channels compound together. The financing risk remains, but operationally this quarter looks like meaningful progress toward break-even.

$AIFF HOPE presentation remains scheduled for: Monday, November 16, 2026 5:45 p.m. Eastern / 2:45 p.m. Pacific CTAD 2026, Boston The official program lists it as LB01, titled: “Spectris Treatment in Mild-to-Moderate Alzheimer’s Disease: Topline Results and Secondary Analyses From the HOPE Pivotal Study.” Presenters remain Roy Hamilton, Ralph Kern, Robbert Zusterzeel, and Marwan Sabbagh. CTAD’s current press information also confirms that sessions will be livestreamed, but access requires conference registration. Recordings are expected to be available to registered attendees within 48 hours.

$AIFF Retracting my earlier post The misunderstanding came from mixing three different levels of evidence: 1. A third-party aggregator, SeedOps, reported a statement attributed to Cognito: “Next month at CTAD, we’ll share the results of our pivotal HOPE study.” That appeared in an October 13 activity record and was published later. 2. I treated that aggregator entry as if it were a directly verified Cognito press release or official CTAD program entry. That was my mistake. 3. When I checked Cognito’s website and the CTAD listing, I found only an OVERTURE biomarker poster clearly listed. I then swung too far in the other direction and said the CTAD HOPE announcement was unconfirmed, without adequately acknowledging that the SeedOps entry may have captured a genuine Cognito social-media post.

$AIFF Finally! Just Announced Cognito says it will share results from its pivotal 673-patient HOPE study at CTAD, Nov. 16–19 in Boston. After a long wait, we finally have a defined timeline. For $AIFF, I’ll be watching for any Firefly EEG findings—and whether brain-state changes align with clinical outcomes and MRI. Big potential catalyst; results are still unknown. #Alzheimers

$AIFF Longitudinal Brain state progression

🧠 ADHD Awareness Month puts community at the center of care—from families and clinicians to coaches and peers. An estimated 22 million Americans currently have an ADHD diagnosis, including 6.5 million children and 15.5 million adults. Their needs extend beyond prescriptions to treatment access, school and workplace accommodations, and ongoing support. For investors, companies addressing different parts of this care network include: 💊 $CING — Investigational once-daily ADHD medication 🧠 $AIFF — Brain-function assessment technology 🧬 $MYGN — Genetic insights to inform psychiatric prescribing 💤 $VVOS — Pediatric sleep-apnea technology, not an ADHD treatment 🔬 $BWAY — Investigational Deep TMS research in adults with ADHD The key distinction: commercial offerings, regulatory clearances, and investigational treatments are not interchangeable. Clinical evidence, regulatory milestones, and demonstrated revenue matter. #ADHDAwarenessMonth #ADHD #MentalHealth #Biotech

$AIFF has provided an update on its non-invasive brain-computer interface (BCI) strategy, highlighting the role of its commercially available Versus platform in pursuing the human-performance market. https://biotuesdays.com/2026/10/28/firefly-strengthens-bci-growth-strategy-with-commercially-available-platform/

$AIFF $BRAI AIFF should be 5$ here